Trial Profile

Idelalisib Plus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: a Phase 2, Single-arm, Multicentric Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idelalisib (Primary) ; Obinutuzumab (Primary)
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms FIL_GAUDEALIS; GAUDEALIS
Sponsors Fondazione Italiana Linfomi

Most Recent Events

05 Jul 2023 Status changed from active, no longer recruiting to discontinued.
26 Nov 2021 Planned End Date changed from 6 Apr 2023 to 29 Apr 2023.
07 May 2021 Planned End Date changed from 18 Oct 2025 to 6 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com